33 results about "Glutaredoxin" patented technology

The mechanism of action of Ebselen differentiates between bacterial and mammalian thioredoxin reductase (TrxR). It displays fast oxidation of mammalian Trx and via the NADPH-TrxR catalyzed turnover of ebselen selenol with hydrogen peroxide, and therefore are mammalian antioxidants. Ebselen, and its diselenide, are strong competitive inhibitors of E. coli TrxR with Ki of 0.14 μM and 0.46 μM, respectively. E. coli mutants lacking glutathione reductase or glutathione were much more sensitive to inhibition by ebselen. Since either glutaredoxin or thioredoxin systems are electron donors to ribonucleotide reductase, ebselen targets primarily glutathione and glutaredoxin-negative bacteria, a class which includes major pathogens. Ebselen, and similar compounds are therefore useful as antibacterial agents, even for multiresistant strains. Two major pathogenic bacteria, which previously had not been known to be sensitive to ebselen, Mycobacterium tuberculosis (tuberculosis) and Helicobacter pylori (stomach ulcer and cancer), were shown to be excellent targets. Helicobacter pylori was also sensitive to ebsulfur.

The mechanism of action of Ebselen differentiates between bacterial and mammalian thioredoxin reductase (TrxR). It displays fast oxidation of mammalian Trx and via the NADPH-TrxR catalyzed turnover of ebselen selenol with hydrogen peroxide, and therefore are mammalian antioxidants. Ebselen, and its diselenide, are strong competitive inhibitors of E. coli TrxR with Ki of 0.14 μM and 0.46 μM, respectively. E. coli mutants lacking glutathione reductase or glutathione were much more sensitive to inhibition by ebselen. Since either glutaredoxin or thioredoxin systems are electron donors to ribonucleotide reductase, ebselen targets primarily glutathione and glutaredoxin-negative bacteria, a class which includes major pathogens. Ebselen, and similar compounds are therefore useful as antibacterial agents, even for multiresistant strains. Two major pathogenic bacteria, which previously had not been known to be sensitive to ebselen, Mycobacterium tuberculosis (tuberculosis) and Helicobacter pylori (stomach ulcer and cancer), were shown to be excellent targets. Helicobacter pylori was also sensitive to ebsulfur.

The present invention discloses and claims compositions, methods of treatment, and kits which cause an increase in the time of survival in cancer patients, wherein the cancer: (i) overexpresses thioredoxin or glutaredoxin and / or (ii) exhibits evidence of thioredoxin- or glutaredoxin-mediated resistance to one or more chemotherapeutic interventions. The present invention also discloses and claims methods and kits for the administration of said compositions to properly treat cancer patients. Additionally, the present invention discloses and claims methods and kits for quantitatively determining the level of expression of thioredoxin or glutaredoxin in the cancer cells of a cancer patient, methods of using those determined levels in the initial diagnosis and / or planning of subsequent treatment methodologies for said cancer patient, as well as ascertaining the potential growth “aggressiveness” of the particular cancer and treatment responsiveness of the particular type of cancer. Further, the present invention discloses and claims novel pharmaceutical compositions, methods, and kits used for the treatment of patients with medical conditions and disease where there is the overexpression of thioredoxin and / or glutaredoxin, and wherein this overexpression is associated with deleterious physiological effects in the patients.

The present disclosure describes genetically-modified plants having enhanced tolerance to multiple abiotic stressors, such as extreme temperatures (heat or cold) and / or drought. Abiotic stress tolerance is enhanced by ectopic expression of a heterologous glutaredoxin. Abiotic stress tolerance (particularly drought) is also enhanced by inhibited function, activity, or expression of an endogenous glutaredoxin. Methods of producing such genetically-modified plants are also disclosed.

The present invention discloses and claims compositions, methods of treatment, and kits which cause an increase in time of survival in cancer patients, wherein the cancer either: (i) overexpresses thioredoxin or glutaredoxin and / or (ii) exhibits evidence of thioredoxin- or glutaredoxin-mediated resistance to one or more chemotherapeutic interventions. The present invention also discloses and claims methods and kits for the administration of said compositions to properly treat cancer patients. Additionally, the present invention discloses and claims methods and kits for quantitatively determining the level of expression of thioredoxin or glutaredoxin in the cancer cells of a cancer patient, methods of using those determined levels in the initial diagnosis and / or planning of subsequent treatment methodologies for said cancer patient, as well as ascertaining the potential growth 'aggressiveness' of the particular cancer and treatment responsiveness of the particular type of cancer. Further, the present invention discloses and claims novel pharmaceutical compositions, methods, and kits used for the treatment of patients with medical conditions and disease where there is the overexpression of thioredoxin and / or glutaredoxin, and wherein this overexpression is associated with deleterious physiological effects in the patients.

The invention discloses a tomato glutaredoxin gene SlRX1 as well as a cloning method and application thereof. The tomato glutaredoxin gene SlRX1 is a first glutaredoxin gene separated from tomatoes, consists of 1,003 basic groups and is used for coding CGFS glutaredoxin forced and induced in environments of drought, high salt, and the like. The gene can be expressed in roots, stems, leaves and petals of the tomatoes and participates in an anti-nonbiostress reaction of plants. If the gene is silent in tomatoes, the tomatoes are more sensitive to the environments draught, high salt, oxidativestress, and the like, and if the gene is excessively expressed in arabidopsis thaliana, the resistance to the environments of draught, high salt and oxidativestress of transgenic arabidopsis thaliana. The gene can improve the resistance of plants to the environments of draught, high salt and oxidativestress and has strong theoretical research and application values.

The invention belongs to the technical field of plant gene engineering, and particularly relates to rubber tree glutaredoxin HbGRX, and further discloses application of the rubber tree glutaredoxin HbGRX to the field of selection of rubber tree tapping panel dryness resistant varieties. According to the method, the fact that the expression of the rubber tree glutaredoxin HbGRX in a rubber tree with tapping panel dryness shows up an obvious reducing trend is verified through gene cloning performed on the rubber tree glutaredoxin HbGRX and analysis and research on biological information and expression performance, visibly GRX as antioxidant enzyme can effectively eliminate a large amount of accumulated laticiferous cell active oxygen, has close correlation with rubber tree tapping panel dryness, can be effectively applied to the field of prevention and control of rubber tree tapping panel dryness, lays a powerful theoretical foundation for illuminating a rubber tree tapping panel drynessoccurrence mechanism, and further provides a scientific basis for the research and development of a rubber tree tapping panel dryness prevention and control technology and breeding of tapping panel dryness resistant rubber tree new variety through molecular selection.

The invention relates to the field of food technology, in particular to a method for evaluating the allergenicity of natural bee pollen and fermented bee pollen based on oleosin and glutaredoxin characteristic peptide indexes. This invention proposes for the first time that oleosin (Oleosin B2) and glutaredoxin (Glutaredoxin) are used as the evaluation index of untreated natural bee pollen or fermented bee pollen allergenicity evaluation, and provides a specific evaluation process accordingly . At the same time, on the basis of the specific protein evaluation method, the present invention further proposes to further verify the evaluation results of the allergenicity of bee pollen by detecting the content of oligopeptides and amino acids in the methanol extract of bee pollen as a supplementary means. The evaluation method of the invention has the advantages of high accuracy, convenience and quickness, and provides evaluation basis for standardized production and quality control of bee pollen.

The invention discloses a Neospora attenuated strain with double deletion of grx S16 and grx C5 genes, and a construction method and application thereof. This strain is missing the glutaredoxin S16 gene (grx S16) and the glutaredoxin C5 gene (grx C5) of Neospora. The nucleotide sequences of the grx S16 gene and the grx C5 gene are shown in SEQ ID NO.1, respectively. and SEQ ID NO.2. The reproductive capacity and virulence of the Neospora grx S16 and grx C5 double gene deletion strains constructed by the present invention are significantly reduced, and can effectively resist the re-infection of Neospora after inoculating mice, and has the ability to become a Neospora attenuated vaccine. potential.

Compositions and methods for improving plant growth are provided herein. Polynucleotides encoding glutaredoxin proteins, polypeptides encompassing glutaredoxin proteins, and expression constructs for expressing genes of interest whose expression may improve agronomic properties including but not limited to crop yield, biotic and abiotic stress tolerance, and early vigor, plants comprising the polynucleotides, polypeptides, and expression constructs, and methods of producing transgenic plants are also provided.

Compositions and methods for improving plant growth are provided herein. Polynucleotides encoding glutaredoxin proteins, polypeptides encompassing glutaredoxin proteins, and expression constructs for expressing genes of interest whose expression may improve agronomic properties including but not limited to crop yield, biotic and abiotic stress tolerance, and early vigor, plants comprising the polynucleotides, polypeptides, and expression constructs, and methods of producing transgenic plants are also provided.

Oxygenic photosynthesis is the major site of production of reactive oxygen species (ROS). Under high temperature stress, increased ROS damage the photosynthetic machinery, membranes and proteins of plants. The present invention is directed to methods for increasing the stress tolerance of plants by expressing PvGrx5 in the plants.

The present invention discloses and claims compositions, methods of treatment, and kits which cause an increase in time of survival in cancer patients, wherein the cancer either: (i) overexpresses thioredoxin or glutaredoxin and / or (ii) exhibits evidence of thioredoxin- or glutaredoxin-mediated resistance to one or more chemotherapeutic interventions. The present invention also discloses and claims methods and kits for the administration of said compositions to properly treat cancer patients. Additionally, the present invention discloses and claims methods and kits for quantitatively determining the level of expression of thioredoxin or glutaredoxin in the cancer cells of a cancer patient, methods of using those determined levels in the initial diagnosis and / or planning of subsequent treatment methodologies for said cancer patient, as well as ascertaining the potential growth 'aggressiveness' of the particular cancer and treatment responsiveness of the particular type of cancer. Further, the present invention discloses and claims novel pharmaceutical compositions, methods, and kits used for the treatment of patients with medical conditions and disease where there is the overexpression of thioredoxin and / or glutaredoxin, and wherein this overexpression is associated with deleterious physiological effects in the patients.

The present invention discloses and claims compositions, methods of treatment, and kits which cause an increase in the time of survival in cancer patients, wherein the cancer: (i) overexpresses thioredoxin or glutaredoxin and / or (ii) exhibits evidence of thioredoxin- or glutaredoxin-mediated resistance to one or more chemotherapeutic interventions. The present invention also discloses and claims methods and kits for the administration of said compositions to properly treat cancer patients. Additionally, the present invention discloses and claims methods and kits for quantitatively determining the level of expression of thioredoxin or glutaredoxin in the cancer cells of a cancer patient, methods of using those determined levels in the initial diagnosis and / or planning of subsequent treatment methodologies for said cancer patient, as well as ascertaining the potential growth “aggressiveness” of the particular cancer and treatment responsiveness of the particular type of cancer. Further, the present invention discloses and claims novel pharmaceutical compositions, methods, and kits used for the treatment of patients with medical conditions and disease where there is the overexpression of thioredoxin and / or glutaredoxin, and wherein this overexpression is associated with deleterious physiological effects in the patients.

The invention relates to the technical field of biology, and concretely discloses application of echinococcus granulosa glutaredoxin-1 to preparation of an immunizing antigen and / or a kit for detecting echinococcosis granulose. When being used as an immunizing antigen, the echinococcus granulosa glutaredoxin-1 can be recognized by sheep positive blood serum naturally infecting the echinococcosis granulose. When being applied to indirect ELISA detection, the echinococcus granulosa glutaredoxin-1 has high specificity and sensitivity; the clinic detection coincidence rate is as high as 97.9 percent. The detection method built by using the echinococcus granulosa glutaredoxin-1 as the immunizing antigen has a good diagnosis effect, and can be used for the primary screening of the echinococcus granulosa of sheep in an infected area.

The invention provides recombinant buckwheat glutaredoxin as well as a preparation method and application thereof. The preparation method comprises the steps of constructing the recombinant buckwheat glutaredoxin (rbGrx) onto a pGEX-6p-1 carrier, transforming into escherichia coli BL21 (DE3), and performing induced expression on fusion protein connected with GST; carrying out enzyme digestion, and then using an anion exchange column and a gel column for further purifying to obtain the rbGrx with the purity of 98% or more. Then, culture is carried out under the crystallization conditions of pH being 4.5, 22% of PEG 3350 (W / V) and 0.1M of CH3COONa, so that a compound crystal of the rbGrx and glutathione (GSH) is obtained; the structure of the compound crystal is measured by an X-ray single-crystal diffraction method, so that important amino acid residues related to catalytic activity can be clearly distinguished, and the stability and enzyme activity are further regulated and controlled purposefully. The rbGrx also has high thioltransferase activity, and the enzyme specific activity is 300U / mg. The rbGrx can be applied to a catalytic thiol transfer reaction, and the crystal and structure of the rbGrx also have a practical value in the aspects of health care, food development, and the like.

The invention relates to the technical field of plant genetic engineering, in particular to the application of a cucumber glutaredoxin gene CsGRX4 and its botrytis susceptibility. The invention finds that a cucumber glutaredoxin gene CsGRX4 is infected with the corresponding pathogenic fungus Botrytis cinerea, and its overexpression can obviously improve the susceptibility to the pathogenic fungus Botrytis cinerea. After quantitative inoculation of Botrytis cinerea spore suspension, the lesion area of ​​the transgenic lines overexpressing CsGRX4 was significantly larger than that of the wild-type control. The above results indicated that the overexpression of cucumber glutaredoxin gene CsGRX4 in Arabidopsis increased the transgenic Arabidopsis) susceptibility to the pathogenic fungus Botrytis cinerea.